secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-029065
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology reports Q4 cash $91.7M; 64% ORR for onvansertib plus SOC in RAS-mut mCRC
--------------------------------------------------------------------------------

- 64% objective response rate (ORR) for 30mg onvansertib + SOC vs 33% control in first-line RAS-mut mCRC trial (CRDF-004).
- Raised $40M oversubscribed registered direct offering; cash runway extended into Q1 2027.
- Full-year 2024 net cash used $37.7M; operating expenses $49.3M, up $3.4M YoY.
- USPTO issued patent for onvansertib + bev in bev-naïve KRAS-mut mCRC, expiring no earlier than 2043.
- Additional CRDF-004 clinical data expected in 1H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000095017025029065/0000950170-25-029065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000095017025029065/crdf-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-029065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer